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Cutaneous leukocytoclastic vasculitis arises from immune complex deposition and dys-
regulated complement activation in small blood vessels. There are many causes, includ-
ing dysregulated host response to infection, drug reactions, and various autoimmune 
conditions. It is increasingly recognised that some monogenic autoinflammatory diseases 
cause vasculitis, although genetic causes of vasculitis are extremely rare. We describe 
a child of consanguineous parents who presented with chronic cutaneous leukocyto-
clastic vasculitis, recurrent upper respiratory tract infection, and hypocomplementaemia. 
A homozygous p.His380Arg mutation in the complement factor I (CFI) gene CFI was 
identified as the cause, resulting in complete absence of alternative complement path-
way activity, decreased classical complement activity, and low levels of serum factor I, 
C3, and factor H. C4 and C2 levels were normal. The same homozygous mutation and 
immunological defects were also identified in an asymptomatic sibling. CFI deficiency 
is thus now added to the growing list of monogenic causes of vasculitis and should 
always be considered in vasculitis patients found to have persistently low levels of C3 
with normal C4.
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BaCKGRoUND
Leukocytoclastic vasculitis (LV) is the term commonly used to describe histopathological findings 
of small vessel vasculitis characterized by leukocytoclasis and the presence of nuclear debris from 
infiltrating neutrophils. LV commonly affects the skin (cutaneous LV, CLV), and typically presents as 
palpable purpura of the lower extremities (1, 2). Circulating immune complexes, sometimes triggered 
by drugs or infections, are deposited within small blood vessels and incite an inflammatory response 
which includes activation of complement, resulting in small vessel vasculitis (3–5). CLV should not 
be regarded as a specific diagnosis in itself, since there are many underlying causes, including the 
primary systemic vasculitides [such as the antineutrophil cytoplasmic antibody (ANCA) associated 
vasculitides, IgA vasculitis, and many others]; drug reactions and other causes of hypersensitivity 
vasculitis; and various autoimmune connective tissue diseases (1, 6, 7). Increasingly, however, it is 
recognised that vasculitis (including LV) may be a presenting feature of an ever expanding list of 
monogenic autoinflammatory diseases, including: deficiency of adenosine deaminase type 2 (8, 9); 
FIGURe 1 | (a) Cutaneous vasculitis over both lower extremities of the index case [V-2; (C)]. (B) Skin biopsy of the lesion showing a dermal perivascular and 
interstitial infiltrate of predominantly neutrophils and nuclear dust which is compatible with leukocytoclastic vasculitis (haematoxylin & eosin stain, high magnification). 
(C) Family pedigree. (D) Sanger sequencing confirmed a homozygous G/G mutation (single black line) at position 1,139 of complement factor I gene in the index 
case and the asymptomatic brother; a heterozygous A/G state (Green/black line) was confirmed in both parents.
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STING-associated vasculitis of infancy (10); and other emerging 
genetic immunodysregulatory diseases (11); monogenic defects 
in complement (12, 13); and miscellaneous even rarer genetic syn-
dromes (14). Most cases of CLV are, however, ultimately deemed 
idiopathic (1, 15).
The complement system is a complex and evolutionarily 
ancient component of the innate immune system. It is the first 
line of defense against invading organisms or foreign proteins, 
and enhances antibody function and phagocytosis (16). 
Activation of classical, alternative, or lectin complement path-
ways are documented in several vasculitides including urticarial 
vasculitis (17, 18), and ANCA-associated vasculitis (19). The 
complement system is composed of more than 30 proteins that 
function as complement cascade components, or system regula-
tors (20). Genetic mutations of [including loss-of-function or 
gain-of-function (GOF) mutations], or autoantibodies directed 
to specific complement proteins can result in a broad spectrum of 
severe immunological sequelae that includes: recurrent bacterial 
infections, autoimmunity, paroxysmal nocturnal haemoglobinu-
ria, glomerulonephritis, atypical haemolytic uremic syndrome 
(aHUS; typically associated with mutation in factor H, heterozy-
gous mutations in: factor I, C3 or factor B; and mutations lead-
ing to membrane co-factor protein deficiency), and hereditary 
angioedema (associated with C1 esterase inhibitor deficiency) 
(20–22). Herein, we describe a child with recessive mutation in 
complement factor I (CFI) with deficiency of CFI causing chronic 
CLV and recurrent bacterial infections.
Case pReseNtatIoN
The index case was a female born to consanguineous Pakistani 
parents. She was well during the first year of life and tolerated her 
primary immunisations including BCG. From the second year 
of life she developed recurrent episodes of purulent otitis media 
(4 to 6 episodes per year) requiring multiple courses of antibiot-
ics; although bacterial otitis was inconsistently documented, 
Staphylococcus aureus was detected on at least one occasion. She 
developed hearing loss secondary to these episodes, and required 
hearing aids. At the age of 3  years she developed a recurrent 
vasculitic rash affecting her arms, legs, and lower abdomen with 
palpable purpura (Figure 1A) this was associated with abdomi-
nal pain and arthralgia of the knees suggestive of a diagnosis of 
chronic IgA vasculitis (previously referred to as Henoch Schönlein 
purpura). Renal function and blood pressure were normal, and 
there was no evidence of proteinuria. Skin biopsy at that stage 
revealed a dermal perivascular (mainly surrounding capillaries) 
and interstitial infiltrate composed predominantly of neutrophils 
and nuclear dust (Figure  1B). Direct immunofluorescence 
for IgG, IgA, IgM, and C3 was negative. A second skin biopsy 
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pneumonia complicated by empyema that required drainage 
and intravenous antibiotics, although no organism was cultured 
during that episode. Between the age of 5 and 6 years she devel-
oped two further episodes of lower respiratory tract infection 
requiring antibiotics, and had persistent cutaneous vasculitis 
despite intermittent courses of oral prednisolone (1–2  mg/kg/
day), and daily azathioprine (1–3 mg/kg). Therefore, at the age of 
7 years she was referred to Great Ormond Street Hospital NHS 
Foundation Trust (GOSH) for further investigation of persistent 
cutaneous vasculitis and recurrent infection.
The family history (Figure 1C) revealed that parents were first 
cousins and were clinically well; her brother (aged 11 years) was 
also fit and well. Moreover, after specific enquiry, there was no 
history of recurrent or severe infections in the brother (V-1), or 
in either parent. There was also no confirmed family history of 
autoimmunity or immunodeficiency. On review of systems of the 
index case, there was no current history of prolonged or periodic 
fevers, arthralgia, or other systemic features. Physical examina-
tion demonstrated an injected left middle ear with effusion; 
and vasculitic rash affecting the lower limbs (Figure 1A). Blood 
pressure was normal, and there was no significant proteinuria or 
other organ specific involvement with vasculitis.
Laboratory investigations (Table S1 in Supplementary 
Material) revealed a high erythrocyte sedimentation rate of 
60 mm/hr, and normal C-reactive protein of 6 mg/L [reference 
range (RR) <20]. All full blood count parameters were within 
normal limits. Rheumatoid factor was positive (59 international 
units/ml; RR 0–20). Other autoantibodies (antinuclear antibody; 
ANCA, including anti-proteinase 3 and anti-myeloperoxidase; 
anti-double stranded DNA; anticardiolipin; and against extract-
able nuclear antigens) were all negative. Notably, she had a 
persistently low serum C3 of 0.22 g/L (RR 0.75–1.65 g/L) with 
normal C4 of 0.36  g/L (RR 0.1–0.54  g/L) and decreased func-
tion of alternative (0% of healthy control) and classical (5% of 
healthy control) complement pathways. Low C3, normal C4, 
absent alternative complement pathway activity, and markedly 
decreased classical complement pathway activity persisted dur- 
ing follow up (measured on four separate occasions over 2 years), 
and prompted more detailed scrutiny of the complement pathway.
Work Up for suspected Complement 
Deficiency
Table 1 summarizes the genotype and results of complement stud-
ies. All experimental work was performed with ethical approval 
(ethics number 08H071382) with written informed  consent 
from all adult participants, and parental consent, and assent for 
children. Whole-exome sequencing (WES) was performed in the 
index case. C3 and C4 measurements were performed by the 
immunology laboratory at GOSH using a standard nephelometry 
assay (BN II Siemens Healthcare, UK). Classical and alterna-
tive complement assays (EuroDiagnostics, Sweden) and MBL 
assays were performed by enzyme-linked immunosorbent assay 
(ELISA). CFI and H were measured at Pathology Imperial College 
Healthcare, NHS, UK using ELISA (Binding Site, UK). C1q was 
measured by radial immunodiffusion and C1q antibodies by 
ELISA at the Protein Reference Unit in Sheffield, UK.
FIGURe 2 | Overview of complement factor I (CFI) function. (a) CFI inhibits both the classical and lectin complement pathways by deactivation of C4bC2a complex. 
Surface-bound C4bC2a activating complex is bound by C4b-binding protein (C4BP) leading to the dissociation of C2a. CFI subsequently binds to the C4b-C4BP 
complex leading to the cleavage of C4b into C4c and C4d. (B) CFI deactivates complement receptor 1 (CR1)/CD35-bound C3b. Membrane cofactor protein (MCP/
C46) binds to C3b-CR1 complex. The association of CFI results in the cleavage of C3b. (C) CFI inhibits the alternative complement pathway by deactivation of C3b: 
surface-bound C3b is cleaved into iC3B and C3d by factor H and CFI. Thus, whilst CFI is a major regulator of both the classical and alternative complement 
pathways, the alternative pathway is most affected, hence C3 is typically much lower than C4 in cases of CFI deficiency (see main text). Furthermore, since factor H 
is an important regulator of the alternative pathway, secondary factor H deficiency is observed in CFI deficiency (see main text).
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Whole-exome sequencing of the proband revealed a homozy-
gous missense mutation (c.1139A > G; p.His380Arg) in the CFI 
gene that encodes CFI, an important complement regulatory 
factor that downregulates complement activation by cleaving C3b 
and C4b (23). This p.His380Arg mutation was predicted to be del-
eterious by in silico prediction algorithms, including Polyphen-2, 
SIFT, or GERP++, and is highly conserved between organisms 
according to the PhyloP algorithm. This homozygous mutation was 
confirmed to be present using Sanger sequencing in the index case 
(Figure 1C), and has very recently been described in homozygotic 
state in a single case with CFI deficiency (24). There were no other 
class 4 or 5 genetic variants (25) detected by WES in any of the 
complement pathway genes (including CFH), or in any other gene 
in the index case. Sanger sequencing in other family members 
confirmed that both parents were heterozygous for this mutation; 
and that her asymptomatic brother (V-1) was also homozygous 
for this mutation (Figure 1D). Subsequently, detailed complement 
studies were undertaken in the index case and the other first-
degree family members. These results are summarized in Table 1. 
Both the index case (V-2) and the asymptomatic brother (V-1) had 
markedly low CFI levels, whilst the level in the parents was not 
reduced compared to controls. The C3 level in the index case and 
the brother were also reduced, but was normal in both parents. 
The classical and alternative complement assays were reduced in 
the index case, and brother; both parents had normal complement 
assays for all functional assays and individual components tested.
DIsCUssIoN
Complement factor I is located on chromosome 4q25 (26) and 
encodes CFI, a serum glycoprotein produced mainly in the liver 
by hepatocytes. CFI is an important complement activation regula-
tor (18); the major transcript (NM_000204) consists of 13 exons 
corresponding to a single heavy chain and a single light chain on 
the protein domain, linked by two disulphide bonds (23). The light 
chain harbours the serine protease (SP) domain, responsible for 
the catalytic activity of CFI (27). CFI regulates the activation of both 
the classical and alternative complement systems, but is particu- 
larly important for regulating the alternative pathway. CFI deac-
tivates C3b and C4b by cleaving C3b into iC3b and C3d and C4b 
into C4c and C4d. To perform its function, CFI requires several 
cofactors, such as C4b-binding protein (C4BP), complement factor 
H, complement receptor 1 (CR1/CD35), and membrane cofactor 
protein (MCP/CD46); Figure  2 (21). Mono-allelic or bi-allelic 
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mutations in CFI result in two different phenotypes of immu-
nological disease. Heterozygous mutations in CFI are associated 
with aHUS, a severe disease characterized by systemic thrombotic 
microangiopathy (28–30). Bi-allelic loss-of-function mutations 
in CFI cause CFI deficiency, with less than 20 mutations reported 
in less than 50 cases worldwide (23, 31–35). Persistent alterna-
tive complement pathway activation (low C3 with normal C4) 
provided the clue to CFI deficiency, which was confirmed using 
WES in the index case. Low C3 can also be caused by bi-allelic loss-
of-function C3 mutations, or mono-allelic GOF C3 mutations (36). 
Our kindred did not have any mutations in C3 (data not shown), 
thus excluding these important differential diagnoses.
Complement factor I deficiency results in uncontrolled ampli-
fication of C3 cleavage, which leads to consumptive C3 deficiency. 
As a result, patients with CFI deficiency have a defect in bacte-
rial opsonisation leading to an increase in the susceptibility to 
recurrent pyogenic infections (Haemophilus influenzae, Neisseria 
meningitides, and Streptococcus pneumoniae), or non-bacterial 
infection. C3 consumption and dysregulation of the comple-
ment system may also lead to defects in clearance of immune 
complexes, and autoimmune organ injury, particularly glomeru-
lonephritis or (more rarely) vasculitis (23, 30, 31, 34, 37, 38). 
The homozygous CFI p.His380Arg mutation we identified is a 
mutation in the light chain domain, which is responsible for the 
catalytic activity and disulfide bond subsection of CFI. Therefore, 
mutation of this position could affect both the catalytic cleav-
age function and post-translational structural modification of 
CFI. This amino acid is highly conserved across species, and 
the p.His380Arg mutation is predicted to be deleterious by all 
pathogenic prediction algorithms (Table S2 in Supplementary 
Material). Indeed, this mutation has recently been described as 
the cause of CFI deficiency in a 4-year-old patient (24) which 
taken alongside our report now irrefutably confirms its patho- 
genicity.
Functional complement assays of the index case (V-2) and the 
brother (V-1) revealed markedly decreased serum CFI, C3, CFH, 
and decreased activity of both the alternative and classical comple-
ment pathways. These results reflect the increased activation of both 
alternative and classical complement pathways. Known disease-
causing mutations in CFI have been identified in both the light chain 
and heavy chains, and affect different functions and properties 
of CFI, including catalytic and secretory function (30). Persistently 
low C3 with normal C4 levels in our homozygous siblings suggests 
that the classical pathway was less compromised than the alternative 
pathway. This observation is explained by the fact that the classical 
pathway only requires very low concentrations (<0.1%) of its com-
ponents to operate, whereas the alternative pathway requires higher 
concentrations (>5%) (39); hence, whilst CFI deficiency results in 
severe dysregulation of both alternative and classical pathways, the 
classical pathway is less affected and retains some function.
Dysregulation of the alternative complement pathway also 
explains the low factor H we observed (in the absence of any CFH 
mutations detected in this kindred) in our two patients with CFI 
deficiency (Table 1), since the principal function of factor H is to 
regulate the alternative pathway. Low levels of factor H are also 
described in other reports of CFI deficiency (24, 40, 41) and is 
secondary to consumption of the regulatory factor H presumably 
as a compensatory response to excessive and dysregulated alter-
nate pathway activation.
The C1q antibodies we detected in our index case on a single 
occasion, in the face of normal C1q levels, are of dubious clinical 
significance and probably represent a non-specific epiphenom-
enon. In hypocomplementemic urticarial vasculitis there is a 
marked and selective reduction of serum C1q, in association 
with autoantibodies to the collagen-like region of C1q, which 
bind to C1q, activating the complement pathway (42, 43) There-
fore, whilst we cannot completely exclude the possibility that 
C1q antibodies might play some secondary role to explain the 
vasculitic phenotype, the fact that our index case had normal C1q 
levels, low CFI, low C3, and low alternative pathway function 
which segregated perfectly with the genotype in this pedigree, 
and the finding of a second case of CFI recently published due 
to this same homozygous CFI mutation now irrefutably prove 
that it is indeed the CFI deficiency that is the main driver of the 
phenotype, and not primarily C1q autoantibodies.
Interestingly, the brother who also was homozygous for the 
p.His380Arg CFI mutation and had abnormal alternative and 
classical complement function, and low CFI, CFH, and C3 
levels, is currently well, and without any history of recurrent 
infections. Completely asymptomatic, and mildly symptomatic 
individuals with confirmed CFI deficiency have also been 
previously described in other kindreds, but without any clear 
explanation for this variability in predisposition to infection 
(31, 44). Furthermore, reports of recurrent infections (including 
of the respiratory and urinary tract) have also been reported to 
occur with increased frequency in patients with heterozygotic 
CFI mutation and partial CFI deficiency (45). That said, there 
was no history of increased frequency or severity of infection in 
the heterozygotic parents of our kindred.
Therapeutic options for autoimmunity/autoinflammation asso-
ciated with CFI deficiency are limited. Antibiotic prophylaxis and 
vaccination against encapsulated bacteria are pragmatic approaches 
to prevent infection (31, 44), which currently we have recom-
mended for both the children described herein. It is also possible 
that institution of a tailored vaccination programme may improve 
outcomes for individuals with partial CFI deficiency as well (24, 45).
Regarding vaccination, although the production of specific 
antibodies against polysaccharides should not be affected by CFI 
deficiency, these individuals may have faster waning of antibody 
than healthy individuals (35), which could influence frequency 
of booster vaccinations. It is notable that treatment of the vascu-
litis with immunosuppression (azathioprine) in the index case was 
unsuccessful, and arguably could have contributed to the burden of 
infection. CFI replacement (e.g., with regular infusions of plasma) 
(41), would seem to have a logical approach, since it may control C3 
consumption and ameliorate the vasculitic manifestations, although 
at the time of writing we have not yet fully explored this option. Last, 
we are unaware of any attempts to use liver transplantation to correct 
CFI deficiency, although at least in theory this might be a logical and 
definitive approach, albeit risky, and possibly not justifiable-based 
relative risks versus potential benefits in this context.
Thus, the spectrum of vasculitis caused by single gene mutations 
continues to expand, and CFI deficiency (or other genetic cause of 
alternative complement pathway dysregulation) should always be 
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considered in patients with ANCA negative vasculitis, particularly 
when associated with low serum C3, but normal C4 levels.
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